Evidence map›Paper›PMID 42786385›Full record

ArticleJournal of neurology2026

The link between plasma and cognitive markers for Alzheimer's disease in Down syndrome: a longitudinal study.

Alberto Fernández, Elisa M Molanes-López, Pilar Zuluaga, Lucía Vaquero, Fernando Moldenhauer, José M Galván-Román, Ricardo Bajo, Natalia Lagunas, Javier García-Alba

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alberto FernándezDepartment of Legal Medicine, Psychiatry and Pathology, Complutense University of Madrid, 28040, Madrid, Spain.
Elisa M Molanes-LópezDepartment of Statistics and Operational Research, Complutense University of Madrid, 28040, Madrid, Spain.
Pilar ZuluagaDepartment of Statistics and Operational Research, Complutense University of Madrid, 28040, Madrid, Spain.
Lucía VaqueroResearch Group in Digital Culture and Social Movements and Department of Experimental Psychology, Cognitive Processes and Speech Therapy, Complutense University of Madrid, 28223, Madrid, Spain.
Fernando MoldenhauerDepartment of Internal Medicine, La Princesa University Hospital/La Princesa Biomedical Research Institute, 28006, Madrid, Spain.
José M Galván-RománDepartment of Internal Medicine, La Princesa University Hospital/La Princesa Biomedical Research Institute, 28006, Madrid, Spain.
Ricardo BajoInstitute of Applied Magnetism, Complutense University of Madrid, 28040, Madrid, Spain.
Natalia LagunasDepartment of Legal Medicine, Psychiatry and Pathology, Complutense University of Madrid, 28040, Madrid, Spain.
Javier García-AlbaCenter for Cognitive and Computational Neuroscience (c3n), Cognitive Neuroscience Research Group, 28040, Madrid, Spain. jgalba@edu.ucm.es.ORCID http://orcid.org/0000-0002-3342-6572

Funding

Ministerio de Ciencia e Innovación PID2019-106772RB-I00
6 · The paper itself

Abstract

backgroundGiven the need to clarify the relationship between biomarkers, cognitive performance, and clinical status in Down syndrome (DS), this longitudinal study examined the influence of baseline clinical diagnosis on the evolution of plasma neurofilament light (NfL) and p-tau217, as well as the predictive value of baseline cognitive performance on biomarker trajectories and clinical conversion within the Alzheimer's disease (AD) continuum.

methods57 adults with DS were classified as asymptomatic (A

resultsBiomarker levels increased significantly over time in pathological groups only, with the greatest increase observed in the D

conclusionThese findings highlight the relevance of episodic memory performance as a predictor of biomarker progression, particularly p-tau217, and support its close association with clinical status and disease progression. The results support the development of screening strategies to identify DS individuals at high risk of rapid cognitive decline and to inform future therapeutic trials.

Indexed as

Alzheimer DiseaseCognition DisordersDown SyndromeNeurofilament Proteinstau ProteinsAdultBiomarkersDisease ProgressionFemaleHumansLongitudinal StudiesMaleMiddle AgedNeuropsychological TestsBiomarkersneurofilament protein LNeurofilament Proteinstau ProteinsAlzheimer’s diseaseDown syndromeEpisodic memoryNfLPlasma markersP-tau217

Identifiers

PMID42786385

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.